(EMN) Eastman Chemical - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2774321002

Additives, Advanced Materials, Chemical Intermediates, Fibers, Polymers

Diversified Chemicals
Market Cap in USD: 7,608m

IPO / Inception: 1993-10-10
Return 12m vs S&P 500: -31.8%

EPS (Earnings per Share)

EPS CAGR: -11.60%
EPS Trend: -20.4%

Last SUE: -0.22
Qual. Beats: 0

Revenue

Rev. CAGR: -5.21%
Rev. Trend: -78.3%

Last SUE: -1.83
Qual. Beats: 0

Dividends

Dividend Yield	4.84%
Yield on Cost 5y	3.70%
Yield CAGR 5y	4.15%
Payout Consistency	98.3%
Payout Ratio	51.1%

Risk via 5d forecast
Volatility	32.0%
Value at Risk 5%th	46.9%
Relative Tail Risk	-10.89%

Reward TTM
Sharpe Ratio	-0.38
Alpha	-41.19
CAGR/Max DD	-0.11

Character TTM
Hurst Exponent	0.337
Beta	1.210
Beta Downside	1.250

Drawdowns 3y
Max DD	48.40%
Mean DD	15.50%
Median DD	10.00%

Description: EMN Eastman Chemical January 07, 2026

Eastman Chemical Company (NYSE: EMN) is a diversified specialty materials producer with operations in the United States, China, and other global markets. Its business is organized into four segments: Additives & Functional Products, Advanced Materials, Chemical Intermediates, and Fibers, each supplying a broad array of chemicals, polymers, and engineered fibers to end-markets such as transportation, construction, electronics, agriculture, and personal-care.

In FY 2023 Eastman generated roughly $13.5 billion in revenue and delivered an adjusted EBITDA margin near 12 %, reflecting strong pricing power in specialty niches despite volatile petrochemical feedstock costs. The company’s growth is tied to macro-drivers like the global shift toward higher-performance, low-VOC coatings, increasing demand for bio-based polymers, and sustained investment in infrastructure that fuels construction-related chemical consumption.

Key sector trends that could influence EMN’s outlook include tightening regulations on phthalate plasticizers, accelerating adoption of sustainable biopolymers, and cyclical pressure from ethylene and propylene price swings. Monitoring these variables alongside Eastman’s capital-expenditure plans for capacity expansion in its Advanced Materials line will be critical for assessing upside potential.

For a deeper dive into EMN’s valuation metrics and peer comparison, you may find ValueRay’s analyst toolkit useful.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (699.0m TTM) > 0 and > 6% of Revenue (6% = 541.4m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -1.29pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 18.07% (prev 14.42%; Δ 3.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.01b > Net Income 699.0m (YES >=105%, WARN >=100%)

Net Debt (4.59b) to EBITDA (1.45b) ratio: 3.15 <= 3.0 (WARN <= 3.5)

Current Ratio 1.76 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (115.4m) change vs 12m ago -2.04% (target <= -2.0% for YES)

Gross Margin 22.83% (prev 23.39%; Δ -0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 60.08% (prev 62.03%; Δ -1.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.31 (EBITDA TTM 1.45b / Interest Expense TTM 219.0m) >= 6 (WARN >= 3)

Altman Z'' 4.46

(A) 0.11 = (Total Current Assets 3.79b - Total Current Liabilities 2.16b) / Total Assets 14.98b

(B) 0.67 = Retained Earnings (Balance) 10.10b / Total Assets 14.98b

(D) 1.07 = Book Value of Equity 9.77b / Total Liabilities 9.14b

Total Rating: 4.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 42.85

1. Piotroski 5.0pt

2. FCF Yield 3.27%

3. FCF Margin 4.42%

4. Debt/Equity 0.88

5. Debt/Ebitda 3.15

6. ROIC - WACC (= -3.33)%

7. RoE 12.02%

8. Rev. Trend -78.32%

9. EPS Trend -20.40%

What is the price of EMN shares?

As of January 12, 2026, the stock is trading at USD 68.76 with a total of 1,365,420 shares traded.
Over the past week, the price has changed by +6.87%, over one month by +13.80%, over three months by +14.12% and over the past year by -17.54%.

Is EMN a buy, sell or hold?

Eastman Chemical has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy EMN.

Strong Buy: 10
Buy: 3
Hold: 7
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the EMN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	72.9	6.1%
Analysts Target Price	72.9	6.1%
ValueRay Target Price	74	7.6%

EMN Fundamental Data Overview January 09, 2026

P/E Trailing = 11.4028
P/E Forward = 10.8578
P/S = 0.843
P/B = 1.3095
P/EG = 4.0225
Beta = 1.242
Revenue TTM = 9.02b USD
EBIT TTM = 943.0m USD
EBITDA TTM = 1.45b USD
Long Term Debt = 4.79b USD (from longTermDebt, last quarter)
Short Term Debt = 290.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.59b USD (from netDebt column, last quarter)
Enterprise Value = 12.19b USD (7.61b + Debt 5.08b - CCE 489.0m)
Interest Coverage Ratio = 4.31 (Ebit TTM 943.0m / Interest Expense TTM 219.0m)
EV/FCF = 30.56x (Enterprise Value 12.19b / FCF TTM 399.0m)
FCF Yield = 3.27% (FCF TTM 399.0m / Enterprise Value 12.19b)
FCF Margin = 4.42% (FCF TTM 399.0m / Revenue TTM 9.02b)
Net Margin = 7.75% (Net Income TTM 699.0m / Revenue TTM 9.02b)
Gross Margin = 22.83% ((Revenue TTM 9.02b - Cost of Revenue TTM 6.96b) / Revenue TTM)
Gross Margin QoQ = 19.66% (prev 22.13%)
Tobins Q-Ratio = 0.81 (Enterprise Value 12.19b / Total Assets 14.98b)
Interest Expense / Debt = 1.06% (Interest Expense 54.0m / Debt 5.08b)
Taxrate = 64.93% (87.0m / 134.0m)
NOPAT = 330.8m (EBIT 943.0m * (1 - 64.93%))
Current Ratio = 1.76 (Total Current Assets 3.79b / Total Current Liabilities 2.16b)
Debt / Equity = 0.88 (Debt 5.08b / totalStockholderEquity, last quarter 5.77b)
Debt / EBITDA = 3.15 (Net Debt 4.59b / EBITDA 1.45b)
Debt / FCF = 11.49 (Net Debt 4.59b / FCF TTM 399.0m)
Total Stockholder Equity = 5.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.65% (Net Income 699.0m / Total Assets 14.98b)
RoE = 12.02% (Net Income TTM 699.0m / Total Stockholder Equity 5.81b)
RoCE = 8.90% (EBIT 943.0m / Capital Employed (Equity 5.81b + L.T.Debt 4.79b))
RoIC = 3.04% (NOPAT 330.8m / Invested Capital 10.87b)
WACC = 6.37% (E(7.61b)/V(12.68b) * Re(10.37%) + D(5.08b)/V(12.68b) * Rd(1.06%) * (1-Tc(0.65)))
Discount Rate = 10.37% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.40%
[DCF Debug] Terminal Value 85.50% ; FCFF base≈477.4m ; Y1≈530.0m ; Y5≈691.6m
Fair Price DCF = 114.2 (EV 17.62b - Net Debt 4.59b = Equity 13.03b / Shares 114.1m; r=6.37% [WACC]; 5y FCF grow 12.71% → 2.90% )
EPS Correlation: -20.40 | EPS CAGR: -11.60% | SUE: -0.22 | # QB: 0
Revenue Correlation: -78.32 | Revenue CAGR: -5.21% | SUE: -1.83 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.27 | Chg30d=-0.074 | Revisions Net=-6 | Analysts=9
EPS next Year (2026-12-31): EPS=6.17 | Chg30d=-0.103 | Revisions Net=-6 | Growth EPS=+14.0% | Growth Revenue=+0.2%

Additional Sources for EMN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle